BACKGROUND: Urinary monocyte chemoattractant protein-1 (MCP-1) and hepcidin are potential biomarkers of renal inflammation. We examined their association with development of diabetic nephropathy (DN) lesions in normotensive normoalbuminuric subjects with type 1 diabetes (T1D) from the Renin-Angiotensin System Study. METHODS: Biomarker concentrations were measured in baseline urine samples from 224 subjects who underwent kidney biopsies at baseline and after 5 years. Fifty-eight urine samples below the limit of quantitation (LOQ, 28.8 pg/mL) of the MCP-1 assay were assigned concentrations of LOQ/√2 for analysis. Relationships between ln(MCP-1/Cr) or ln(hepcidin/Cr) and morphometric variables were assessed by sex using multiple linear regression after adjustment for age, T1D duration, HbA1c, mean arterial pressure, albumin excretion rate (AER) and glomerular filtration rate (GFR). In models that examined changes in morphometric variables, the baseline morphometric value was also included. RESULTS: Baseline mean age was 24.6 years, mean duration of T1D 11.2 years, median AER 6.4 µg/min and mean iohexol GFR 129 mL/min/1.73 m(2). No associations were found between hepcidin/Cr and morphometric variables. Higher MCP-1/Cr was associated with higher interstitial fractional volume at baseline and after 5 years in women (baseline partial r = 0.244, P = 0.024; 5-year partial r = 0.299, P = 0.005), but not in men (baseline partial r = -0.049, P = 0.678; 5-year partial r = 0.026, P = 0.830). MCP-1 was not associated with glomerular lesions in either sex. CONCLUSIONS: Elevated urinary MCP-1 concentration measured before clinical findings of DN in women with T1D was associated with changes in kidney interstitial volume, suggesting that inflammatory processes may be involved in the pathogenesis of early interstitial changes in DN. Published by Oxford University Press on behalf of ERA-EDTA 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Urinary monocyte chemoattractant protein-1 (MCP-1) and hepcidin are potential biomarkers of renal inflammation. We examined their association with development of diabetic nephropathy (DN) lesions in normotensive normoalbuminuric subjects with type 1 diabetes (T1D) from the Renin-Angiotensin System Study. METHODS: Biomarker concentrations were measured in baseline urine samples from 224 subjects who underwent kidney biopsies at baseline and after 5 years. Fifty-eight urine samples below the limit of quantitation (LOQ, 28.8 pg/mL) of the MCP-1 assay were assigned concentrations of LOQ/√2 for analysis. Relationships between ln(MCP-1/Cr) or ln(hepcidin/Cr) and morphometric variables were assessed by sex using multiple linear regression after adjustment for age, T1D duration, HbA1c, mean arterial pressure, albumin excretion rate (AER) and glomerular filtration rate (GFR). In models that examined changes in morphometric variables, the baseline morphometric value was also included. RESULTS: Baseline mean age was 24.6 years, mean duration of T1D 11.2 years, median AER 6.4 µg/min and mean iohexol GFR 129 mL/min/1.73 m(2). No associations were found between hepcidin/Cr and morphometric variables. Higher MCP-1/Cr was associated with higher interstitial fractional volume at baseline and after 5 years in women (baseline partial r = 0.244, P = 0.024; 5-year partial r = 0.299, P = 0.005), but not in men (baseline partial r = -0.049, P = 0.678; 5-year partial r = 0.026, P = 0.830). MCP-1 was not associated with glomerular lesions in either sex. CONCLUSIONS: Elevated urinary MCP-1 concentration measured before clinical findings of DN in women with T1D was associated with changes in kidney interstitial volume, suggesting that inflammatory processes may be involved in the pathogenesis of early interstitial changes in DN. Published by Oxford University Press on behalf of ERA-EDTA 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Ronald Klein; Bernard Zinman; Robert Gardiner; Samy Suissa; Sandra M Donnelly; Alan R Sinaiko; Michael S Kramer; Paul Goodyer; Scot E Moss; Trudy Strand; Michael Mauer Journal: Diabetes Date: 2005-02 Impact factor: 9.461
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Julia M Steinke; Alan R Sinaiko; Michael S Kramer; Samy Suissa; Blanche M Chavers; Michael Mauer Journal: Diabetes Date: 2005-07 Impact factor: 9.461
Authors: Pawel P Wolkow; Monika A Niewczas; Bruce Perkins; Linda H Ficociello; Boguslaw Lipinski; James H Warram; Andrzej S Krolewski Journal: J Am Soc Nephrol Date: 2008-02-06 Impact factor: 10.121
Authors: Helen C Looker; Michael Mauer; Pierre-Jean Saulnier; Jennifer L Harder; Viji Nair; Carine M Boustany-Kari; Paolo Guarnieri; Jon Hill; Cordell A Esplin; Matthias Kretzler; Robert G Nelson; Behzad Najafian Journal: J Am Soc Nephrol Date: 2019-06 Impact factor: 10.121
Authors: Xiangling Wang; John C Lieske; Mariam P Alexander; Muthuvel Jayachandran; Aleksandar Denic; Jerry Mathew; Lilach O Lerman; Walter K Kremers; Joseph J Larson; Andrew D Rule Journal: Am J Nephrol Date: 2016-06-10 Impact factor: 3.754
Authors: Kevin M Wheelock; Jian Cai; Helen C Looker; Michael L Merchant; Robert G Nelson; Gudeta D Fufaa; E Jennifer Weil; Harold I Feldman; Ramachandran S Vasan; Paul L Kimmel; Brad H Rovin; Michael Mauer; Jon B Klein Journal: PLoS One Date: 2017-07-10 Impact factor: 3.240
Authors: Shipra Agrawal; Michael L Merchant; Jiro Kino; Ming Li; Daniel W Wilkey; Adam E Gaweda; Michael E Brier; Melinda A Chanley; Jessica R Gooding; Susan J Sumner; Jon B Klein; William E Smoyer Journal: Kidney Int Rep Date: 2019-09-19